Designing Trials and Deciding on Therapy in Complex Diseases: What Can We Do to Improve?

Abstract

Get full access to this article

View all access options for this article.

References

Johnston JA . Determinants of mortality in patients with severe sepsis. Med Decis Making. 2005;4: 374-386.

Bernard GR , Vincent J-L , Laterre P-F , et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;34: 699-709.

Matthay MA . Severe sepsis—a new treatment with both anticoagulant and anti-inflammatory properties. N Engl J Med. 2001;344(10): 759-762.

Knaus WA , Harrell FE , Fisher CJ , et al. The clinical evaluation of new drugs for sepsis. JAMA. 1993;270: 376-393.

Gail MH , Wieand S , Piantadosi S . Biased estimates of treatment effect in randomized experiments with nonlinear regressions and omitted covariates. Biometrika. 1984;71: 431-444.

American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference . Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20: 864-874.

Knaus WA , Draper EA , Wagner DP , Zimmerman JE . APACHE II: a severity of disease classification system. Crit Care Med. 1985;13: 818-829.

Knaus WA , Harrell FE , LaBrecque MS , et al. Use of predicted risk of mortality to evaluate the efficacy of anticytokine therapy in sepsis. Crit Care Med. 1996;24: 46-56.

Siegel JP . Assessing the use of protein C in the treatment of severe sepsis. N Engl J Med. 2002;347: 1030-1034.

10.

Rice TW , Bernard GR . Drotrecogin alfa (activated) for the treatment of severe sepsis and septic shock. Am J Med Sci. 2004;328(4): 205-214.

11.

Bernard GR , Margolis BD , Shanies HM , et al. Extended evaluation of recombinant human activated protein C United States trial (ENHANCE US)—a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis. Chest. 2004;125: 2206-2216.

12.

Angus DC , Laterre P-F , Hetterbrand J , et al. The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis. Crit Care Med. 2004;32(11): 2199-2206.

13.

Angus DC , Linde-Zwirble WT , Clermont G , et al. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med. 2003;31(1): 1-11.

14.

Mathews AW . Worrisome ailment in medicine: misleading journal articles. Wall Street Journal. 10 May 2005;245(91): A1-A9.

15.

Steinbrook R . Gag clauses in clinical trial agreements. N Engl J Med. 2005;352(21): 2160-2162.

16.

Deans KJ , Minneci PC , Banks SM , Natanson C , Eichacker PQ . Substantiating the concerns about recombinant human activated protein C use in sepsis. Crit Care Med. 2004;32: 2542-2543.

17.

Altman DG , Schulz KF , Moher D , et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med. 2001;134(8): 663-694.

18.

Johnson KC , Connors AF Jr , Wagner DP , Haley EC Jr. Risk adjustment effect on stroke clinical trials. Stroke. 2004;35: e43-e45.

19.

Steyerberg EW , Bossuyt PMM , Lee KL . Clinical trials in acute myocardial infarction: should we adjust for baseline characteristics? Am Heart J. 2000;139: 745-751.